Brian Abrahams

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Brian Abrahams Recent News

Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know
RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data
Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene
After Biogen's Alzheimer's Update, Wall Street Reacts
Incyte Downgraded As RBC Analyst Awaits More Revenue Visbility
Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'
More Data Needed On Proteostasis Therapeutics' Cystic Fibrosis Candidate, RBC Says In Downgrade
Sage Therapeutics Could Still Become A Leader In Neurology
Your Cheat Sheet For Q1 Biotech Earnings
Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets
Gilead Sciences Price Target Trimmed Following A Sobering Q3
Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated
Biogen Downgraded To Hold At Jefferies, Citing Valuation
Jefferies Upgrades Gilead To Buy Citing Bullish Prospects For HIV Franchise
Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies
Jefferies Ponders Whether Gilead Sciences Should Experiment With An HCV Spinoff
Celgene's Phase 3 Study Of REMARC Likely To Be Successful, Says Jefferies
Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold
Mirati Therapeutics Shares Plunge 40%; Jefferies Downgrades To Hold
Gilead's 'R&D Day' Points To Upside For Shareholders
Biotech Investors Still Have Opportunity
Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios BioPharma Deal
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback